化学療法誘発性好中球減少症(CIN)治療薬の世界市場:市場インサイト、疫学分析、市場予測

DelveInsightが発行した調査報告書(DLVE704020)
◆英語タイトル:Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023
◆商品コード:DLVE704020
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年3月
◆ページ数:132
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD4,950 ⇒換算¥554,400見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD9,900 ⇒換算¥1,108,800見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD14,850 ⇒換算¥1,663,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology
and Market Forecast-2023” Report provides an overview of the disease and global market
trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United
States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE)
and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment
practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to
2023 segmented by seven major markets. In addition, the report provides the historical and
forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer
indications till 2023.
The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer,
Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer,
Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin Lymphoma), who are at risk of developing
CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for
chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was
later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute
to majority of the market size, of CIN. However, New Chemical Entities are expected to launch
in the near future. According to DelveInsight, the Global Market size of CIN in 2016 was USD
3.67 Billion.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house Forecast model analysis by Publisher team of industry experts.

【レポートの目次】

Report Introduction
Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance
Global Market Size of CIN in 2016
Global Market Size of CIN in 2023
Chemotherapy Induced Neutropenia (CIN)
Overview
Causes of Neutropenia
Common cycle of chemotherapy-related neutropenia
Signs and symptoms
Risk Factors
Severity and Grades of Neutropenia
Pathophysiology/ Mechanisms of action
Diagnosis
Epidemiology and Patient Population
Assumptions and Caveats
United States
Incident Cases of ten major Cancer indications in United States
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in United States
Ten major cancer patients at low risk of CIN in United States
Ten major cancer patients at intermediate to high risk of CIN in United States
Europe
Germany
Incident Cases of ten major Cancer indications in Germany
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Germany
Ten major cancer patients at low risk of CIN in Germany
Ten major cancer patients at intermediate to high risk of CIN in Germany
United Kingdom
Incident Cases of ten major Cancer indications in United Kingdom
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in United Kingdom
Ten major cancer patients at low risk of CIN in United Kingdom
Ten major cancer patients at intermediate to high risk of CIN in United Kingdom
Italy
Incident Cases of ten major Cancer indications in Italy
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Italy
Ten major cancer patients at low risk of CIN in Italy
Ten major cancer patients at intermediate to high risk of CIN in Italy
Spain
Incident Cases of ten major Cancer indications in Spain
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Spain
Ten major cancer patients at low risk of CIN in Spain
Ten major cancer patients at intermediate to high risk of CIN in Spain
France
Incident Cases of ten major Cancer indications in France
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in France
Ten major cancer patients at low risk of CIN in France
Ten major cancer patients at intermediate to high risk of CIN in France
Japan
Incident Cases of ten major Cancer indications in Japan
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Japan
Ten major cancer patients at low risk of CIN in Japan
Ten major cancer patients at intermediate to high risk of CIN in Japan
Treatment Algorithm
NCCN Guidelines for Chemotherapy Induced Febrile Neutropenia
Evaluation prior to First Chemotherapy Cycle
Overall Febrile Neutropenia Risk
Evaluation Prior to Second and Subsequent Chemotherapy
Therapeutic use of Granulocyte-colony stimulating factor (G-CSF) for Febrile Neutropenia 73
European Organisation for Research and Treatment of Cancer (EORTC)
Marketed Drugs
List of Marketed Drugs
Biosimilar Efficacy
Marketed Drugs Presence
Neupogen: Amgen
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Neupogen
Product Profile
Neupogen Historical Sales (2013-2015)
Neulasta: Amgen
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Neulasta
Product Profile
Neulasta Historical Sales (2013-2015)
Zarxio: Sandoz
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Zarxio
Product Profile
Granix: Teva Pharmaceuticals
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Granix
Product Profile
Lonquex: Teva Pharmaceuticals
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Lonquex
Product Profile
Tevagrastim: Teva Pharmaceuticals
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Filgrastim BS Injection: Fuji Pharma Co., Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Emerging Therapies
Biologicals/ Biosimilar Pipeline
New Chemical Entity (NCE) Pipeline
Pipeline Drugs Results
Plinabulin: BeyondSpring Pharmaceuticals, Inc.
Clinical Development
Advantages & Disadvantages
Product Profile
Rolontis: Spectrum Pharmaceuticals, Inc.
Clinical Development
Advantages & Disadvantages
Product Profile
CHS-1701: Coherus Biosciences
Clinical Development
Advantages & Disadvantages
Product Profile
Myelo001: Myelo Therapeutics GmbH
Clinical Development
Advantages & Disadvantages
Product Profile
Market outlook- Chemotherapy Induced Neutropenia (CIN)
Market Size
Assumptions and Caveats
1. Forecasting Events
2. Drug Categories, Chemotherapy Cycles & Dosage, and Cost Assumptions
Global CIN: Country-Wise Market Analysis
Global Market Size of CIN (2013-2023)
Market Size of CIN in 7MM (2013-2023)
United States
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe (RoE)
Japan
Rest of World (RoW)
Market Drivers
Market Restraints
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Grades of Neutropenia
Table 2: Incident Cases of ten major Cancer indications in United States (2013-2023)
Table 3: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in
United States (2013-2023)
Table 4: Ten major cancer patients at low risk of CIN in United States (2013-2023)
Table 5: Ten major cancer patients at intermediate to high risk of CIN in United States (2013-2023)
Table 6: Incident Cases of ten major Cancer indications in Germany (2013-2023)
Table 7: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in
Germany (2013-2023)
Table 8: Ten major cancer patients at low risk of CIN in Germany (2013-2023) 32
Table 9: Ten major cancer patients at intermediate to high risk of CIN in Germany (2013-2023)
Table 10: Incident Cases of ten major Cancer indications in United Kingdom (2013-2023)
Table 11: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
in United Kingdom (2013-2023)
Table 12: Ten major cancer patients at low risk of CIN in United Kingdom (2013-2023)
Table 13: Ten major cancer patients at intermediate to high risk of CIN in United Kingdom (2013-2023)
Table 14: Incident Cases of ten major Cancer indications in Italy (2013-2023)
Table 15: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
in Italy (2013-2023)
Table 16: Ten major cancer patients at low risk of CIN in Italy (2013-2023)
Table 17: Ten major cancer patients at intermediate to high risk of CIN in Italy (2013-2023)
Table 18: Incident Cases of ten major Cancer indications in Spain (2013-2023)
Table 19: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
in Spain (2013-2023)
Table 20: Ten major cancer patients at low risk of CIN in Spain (2013-2023)
Table 21: Ten major cancer patients at intermediate to high risk of CIN in Spain (2013-2023)
Table 22: Incident Cases of ten major Cancer indications in France (2013-2023)
Table 23: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
in France (2013-2023)
Table 24: Ten major cancer patients at low risk of CIN in France (2013-2023)
Table 25: Ten major cancer patients at intermediate to high risk of CIN in France (2013-2023)
Table 26: Incident Cases of ten major Cancer indications in Japan(2013-2023)
Table 27: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications
in Japan (2013-2023)
Table 28: Ten major cancer patients at low risk of CIN in Japan (2013-2023)
Table 29: Ten major cancer patients at intermediate to high risk of CIN in Japan (2013-2023)
Table 30: List of Marketed Drugs for Chemotherapy Induced Neutropenia
Table 31: Biosimilar Efficacy of Drugs for Chemotherapy Induced Neutropenia
Table 32: Marketed Drugs Presence for Chemotherapy Induced Neutropenia
Table 33: List of Biosimilar Pipeline Drugs for Chemotherapy Induced Neutropenia
Table 34: List of Biosimilar Pipeline Drugs for Chemotherapy Induced Neutropenia
Table 35: Results of Pipeline Drugs for Chemotherapy Induced Neutropenia
Table 36: Global Market size of CIN in USD Billion (2013-2023)
Table 37: Market Size of CIN in 7MM (USD, Billion) (2013-2023)
Table 38: United States Market Size of CIN in USD, Billion (2013-2023)
Table 39: Germany Market Size of CIN in USD, Billion (2013-2023)
Table 40: France Market Size of CIN in USD, Billion (2013-2023)
Table 41: Italy Market Size of CIN in USD, Billion (2013-2023)
Table 42: Spain Market Size of CIN in USD, Billion (2013-2023)
Table 43: United Kingdom Market Size of CIN in USD, Billion (2013-2023)
Table 44: RoE Market Size of CIN in USD, Billion (2013-2023)
Table 45: Japan Market Size of CIN in USD, Billion (2013-2023)
Table 46:RoW Market Size of CIN in USD, Billion (2013-2023)


Figure 1: Incident Cases of ten major Cancer indications in United States (2013-2023)
Figure 2: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in United States (2013-2023)
Figure 3: Ten major cancer patients at low risk of CIN in United States (2013-2023)
Figure 4: Ten major cancer patients at intermediate to high risk of CIN in United States (2013-2023)
Figure 5: Incident Cases of ten major Cancer indications in Germany (2013-2023)
Figure 6: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Germany (2013-2023)
Figure 7: Ten major cancer patients at low risk of CIN in Germany (2013-2023)
Figure 8: Ten major cancer patients at intermediate to high risk of CIN in Germany (2013-2023)
Figure 9: Incident Cases of ten major Cancer indications in United Kingdom (2013-2023)
Figure 10: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in United Kingdom (2013-2023)
Figure 11: Ten major cancer patients at low risk of CIN in United Kingdom (2013-2023)
Figure 12: Ten major cancer patients at intermediate to high risk of CIN in United Kingdom (2013-2023)
Figure 13: Incident Cases of ten major Cancer indications in Italy (2013-2023)
Figure 14: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Italy (2013-2023)
Figure 15: Ten major cancer patients at low risk of CIN in Italy (2013-2023)
Figure 16: Ten major cancer patients at intermediate to high risk of CIN in Italy (2013-2023)
Figure 17: Incident Cases of ten major Cancer indications in Spain (2013-2023)
Figure 18: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Spain (2013-2023)
Figure 19: Ten major cancer patients at low risk of CIN in Spain (2013-2023)
Figure 20: Ten major cancer patients at intermediate to high risk of CIN in Spain (2013-2023)
Figure 21: Incident Cases of ten major Cancer indications in France (2013-2023)
Figure 22: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in France (2013-2023)
Figure 23: Ten major cancer patients at low risk of CIN in France (2013-2023)
Figure 24: Ten major cancer patients at intermediate to high risk of CIN in France (2013-2023)
Figure 25: Incident Cases of ten major Cancer indications in Japan (2013-2023)
Figure 26: Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications inJapan (2013-2023)
Figure 27: Ten major cancer patients at low risk of CIN in Japan (2013-2023)
Figure 28: Ten major cancer patients at intermediate to high risk of CIN in Japan (2013-2023)
Figure 29: Evaluation Prior to Second and Subsequent Chemotherapy
Figure 30: Therapeutic use of Granulocyte-colony stimulating factor (G-CSF) for Febrile Neutropenia
Figure 31: EORTC Patient assessment algorithm to decide prophylactic G-CSF Usage
Figure 32: Historical Sales of Neupogen (2013-2015)
Figure 33: Historical Sales of Neulasta (2013-2015)
Figure 34: Percentage of Market share as per Category (2013-2023)
Figure 35: Global Market Size of CIN in USD, Billion (2013-2023)
Figure 36: Market Size of CIN in 7MM (USD, Billion) (2013-2023)
Figure 37: United States Market Size of CIN in USD, Billion (2013-2023)
Figure 38: Germany Market Size of CIN in USD, Billion (2013-2023)
Figure 39: France Market Size of CIN in USD, Billion (2013-2023)
Figure 40: Italy Market Size of CIN in USD, Billion (2013-2023)
Figure 41: Spain Market Size of CIN in USD, Billion (2013-2023)
Figure 42: United Kingdom Market Size of CIN in USD, Billion (2013-2023)
Figure 43: RoE Market Size of CIN in USD, Billion (2013-2023)
Figure 44: Japan Market Size of CIN in USD, Billion (2013-2023)
Figure 45: RoW Market Size of CIN in USD, Billion (2013-2023)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 化学療法誘発性好中球減少症(CIN)治療薬の世界市場:市場インサイト、疫学分析、市場予測(Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆